The lights have gone green for Bayer’s stock in a way not seen in years. A landmark ruling by the US Supreme Court, combined with the structural carve-out of the company’s US glyphosate business into a new subsidiary called Ruveon, has ignited one of the most powerful moves in the company’s recent history. Over the past 30 days, the share price has surged by nearly 54%, closing Friday at €53.04 and brushing against its 52-week high of €53.86. On an annual basis, the stock has more than doubled — though year-to-date the gain stands at a still robust 39.49%.
The legal breakthrough came from a 7–2 Supreme Court decision in the case Monsanto v. Durnell, which ruled that federal law preempts state-level “failure-to-warn” claims over glyphosate labels. That ruling strips the legal foundation from roughly 200,000 pending lawsuits, offering Bayer a degree of relief that markets had been pricing in only tentatively. The one-day reaction alone was dramatic: on Thursday, the stock jumped 8.9% on Xetra, crossing €50 for the first time since autumn 2023.
The Ruveon Pivot and a Trade Twist
Bayer’s decision to bundle its entire US glyphosate operation into a separate entity, Ruveon LLC, has been interpreted by analysts as more than an administrative reshuffle. Deutsche Bank upgraded the stock to “Buy” with a new target of €60, arguing that a breakup of Bayer’s portfolio is now “only a matter of when and how,” not whether. The carve-out could pave the way for a full sale or spin-off of the glyphosate business, further insulating the parent from legacy liabilities.
But the restructuring has already created a new source of friction. Bayer, Monsanto, and Ruveon have jointly filed a petition with the US Department of Commerce, the USITC, and the Court of International Trade seeking anti-dumping tariffs on Chinese glyphosate imports. That move has drawn sharp criticism from American farming groups — the very same coalitions that had backed Bayer in its Supreme Court fight. The company now risks trading one battlefield for another: from the courtroom to the trade front.
The August Showdown
All eyes are now fixed on a single date: August 19, 2026. That is when a US court will rule on the final approval of Bayer’s $7.25 billion glyphosate settlement package — originally slated for early July. If the judge greenlights the deal, the company can begin to draw a line under years of litigation overhang. A reduced legal bill would dramatically improve free cash flow, which was already negative in the first quarter due to rising legal costs. Without the settlement, Bayer’s legal obligations are expected to consume roughly €5 billion in the near term.
Should investors sell immediately? Or is it worth buying Bayer?
Before that verdict, another critical catalyst arrives on August 4, when Bayer reports second-quarter earnings. The numbers will provide the first real test of how much operational momentum is being stifled by the company’s €32.5 billion net debt pile, which weighed on the balance sheet as of March-end. Management continues to guide for negative free cash flow in 2026, and the interest burden remains heavy.
Overbought, Overheated, and Over-levered
The euphoria, however, has pushed technical indicators into dangerous territory. The relative strength index (RSI) now stands at 85.1, deep in overbought territory and flashing a warning for potential profit-taking. The recent rally rests on a narrow base of legal optimism and restructuring hopes, leaving the stock vulnerable to a sharp reversal if the August 19 hearing does not go Bayer’s way. A rejection of the settlement would send shares tumbling and could quickly erase the year’s hard-won gains.
Beyond the courtroom and the chart, the fundamental picture remains strained. Net debt of €32.5 billion and negative free cash flow suggest that operational progress is being held hostage by legacy costs. Even with the Supreme Court victory, the company must still navigate a thicket of remaining risks: the anti-dumping dispute, ongoing lawsuits not covered by the settlement, and the challenge of revitalising its pharma pipeline, where key oncology and cardiovascular milestones are expected in 2026.
Waiting for the Verdict
The coming weeks will determine whether Bayer’s rally has real legs or is simply a speculative burst ahead of a binary event. The sentiment remains bullish as long as hopes for an August 19 approval hold firm. But with the RSI in the red zone and a heavy debt load still to manage, the margin for error is razor-thin. If the court approves the settlement, a cleaner path forward opens — if it doesn’t, the 104% annual gain could prove painfully fleeting.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from July 4 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 4.
Bayer: Buy or sell? Read more here...
